Segall Bryant & Hamill LLC Acquires Shares of 27,506 IDEXX Laboratories, Inc. $IDXX

Segall Bryant & Hamill LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, Holdings Channel.com reports. The fund bought 27,506 shares of the company’s stock, valued at approximately $16,518,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. SHP Wealth Management purchased a new position in IDEXX Laboratories during the fourth quarter valued at $26,000. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth $26,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Wormser Freres Gestion boosted its holdings in shares of IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares during the last quarter. Finally, WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the second quarter valued at about $30,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IDXX. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group dropped their price target on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a research note on Monday, July 27th. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $749.00.

IDEXX Laboratories Trading Up 0.0%

IDXX opened at $559.07 on Friday. The firm has a market cap of $44.10 billion, a P/E ratio of 41.17, a P/E/G ratio of 3.06 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a 50-day moving average of $557.36 and a 200 day moving average of $590.40.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the firm posted $2.91 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.